-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

BITEs, immune checkpoint molecules, macrophage checkpoint molecules for AML and high grade MDS-

Program: Spotlight Sessions
Session: Immunotherapies for myeloid neoplasms: are we ready for primetime?
Monday, December 12, 2022, 2:45 PM-4:00 PM

Sarit Assouline

Department of Medicine and Oncology, McGill University/Jewish General Hospital, Montreal, QC, Canada; Department of Medicine and Oncology, Jewish General Hospital, McGill University, Montreal, Montreal, QC, Canada

Disclosures: Assouline: Genentech/Roche, Astra Zeneca, Novartis, BMS, Jazz, Gilead, Amgen, Beigene, Abbvie, Paladin: Consultancy, Honoraria; Novartis: Research Funding.

See more of: Immunotherapies for myeloid neoplasms: are we ready for primetime?
See more of: Spotlight Sessions
Previous Presentation | Next Presentation >>